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Abstract
Current treatments for Mycobacterium tuberculosis infections require long and complicated 
regimens that can lead to patient non-compliance, increasing incidences of antibiotic-resistant 
strains, and lack of efficacy against latent stages of disease. Thus, new therapeutics are needed to 
improve tuberculosis standard of care. One strategy is to target protein homeostasis pathways by 
inhibiting molecular chaperones such as GroEL/ES (HSP60/10) chaperonin systems. M. 
tuberculosis has two GroEL homologs: GroEL1 is not essential but is important for cytokine-
dependent granuloma formation, while GroEL2 is essential for survival and likely functions as the 
canonical housekeeping chaperonin for folding proteins. Another strategy is to target the protein 
tyrosine phosphatase B (PtpB) virulence factor that M. tuberculosis secretes into host cells to help 
evade immune responses. In the present study, we have identified a series of GroEL/ES inhibitors 
that inhibit M. tuberculosis growth in liquid culture and biochemical function of PtpB in vitro. 
With further optimization, such dual-targeting GroEL/ES and PtpB inhibitors could be effective 
against all stages of tuberculosis – actively replicating bacteria, bacteria evading host cell immune 
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responses, and granuloma formation in latent disease – which would be a significant advance to 
augment current therapeutics that primarily target actively replicating bacteria.
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Mycobacterium tuberculosis, the causative agent of tuberculosis, infects about 1 in 4 people 
worldwide. In 2017, over 10 million active cases of tuberculosis infection were reported, 
with 1.6 million deaths attributed to this deadly disease.1 M. tuberculosis is a facultative 
intracellular bacterium that is transmitted as an airborne particulate generated when people 
with active tuberculosis cough or sneeze. When inhaled, the bacteria traverse the respiratory 
tract to alveoli where they infect phagocytic cells, namely macrophages.2–4 The bacteria 
replicate within the macrophage and induce cytokines that initiate an inflammatory response 
in the lungs. Macrophages and lymphocytes migrate to the site of infection and form 
granulomas, which lead to asymptomatic latent disease where pools of bacteria can reside in 
dormant states for years. However, a weakened immune system can lead to re-activation of 
dormant M. tuberculosis from the granulomas, allowing bacteria to once again actively 
replicate, which can be fatal if left untreated.
First-line antibiotics to treat tuberculosis include isoniazid, rifampicin, ethambutol, and 
pyrazinamide.1, 3, 5 Unfortunately, these antibiotics are most effective against actively-
replicating bacteria, which is problematic since M. tuberculosis replicates slowly (18–54 h 
doubling times) and can persist in granulomas in a more metabolically inactive state.6 To 
increase treatment efficacy, combination therapy is typically administered for at least six-to-
nine months. This extensive regimen often leads to patient non-compliance, which 
contributes to the development of antibiotic resistant strains. To help combat drug resistance, 
two new drugs have recently been approved – bedaquiline and delamanid.7, 8 Unfortunately, 
resistance is also arising to these two drugs.9–11 Thus, new drug candidates are needed that 
act on previously unexploited targets and pathways not predisposed to resistance, and that 
are additionally effective against the asymptomatic latent phase of infections.
A new paradigm in antibiotic research is to exploit protein homeostasis pathways, such as 
targeting molecular chaperones.12–24 A network of molecular chaperones and proteases 
collectively functions to maintain protein homeostasis by assisting proteins to fold to their 
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native, functional states, or ensuring their proper degradation.25–31 In particular, all 
organisms contain at least one homolog of the 60 kDa class of molecular chaperone (HSP60) 
that is essential under all conditions. Thus, targeting HSP60 chaperonin systems with small 
molecule inhibitors should be an effective antibacterial strategy. Escherichia coli GroEL is 
the prototypical member of the HSP60 chaperonin family, which has been studied 
extensively. GroEL is a homo-tetradecameric protein that forms two, seven-subunit rings 
that stack back-to-back with one another. Through a series of events driven by ATP binding 
and hydrolysis, unfolded substrate polypeptides are bound within the central cavity of a 
GroEL ring and are encapsulated by the GroES co-chaperonin lid, allowing protein folding 
within the sequestered chamber. We refer readers to these other studies for a more detailed 
understanding of the structure and function of GroEL/ES chaperonin systems.32, 33
M. tuberculosis has two GroEL homologs, GroEL1 and GroEL2, which interestingly diverge 
in their sequences and share 61% amino acid identity with each other.34–40 GroEL2 is the 
putative housekeeping molecular chaperone for folding proteins as it is essential for M. 
tuberculosis survival and contains the GGM repeat motif found in the canonical chaperonins 
of other organisms.35 Thus, targeting GroEL2 with small molecule inhibitors should be an 
effective strategy to kill actively replicating M. tuberculosis. While GroEL1 is not essential, 
it is important in regulating cytokine-dependent granuloma formation.35, 38 When infected 
with a strain of M. tuberculosis deficient in GroEL1 (Δcpn60.1), both mice and guinea pigs 
produced equal numbers of bacteria as the WT-GroEL1 strain, but the mutant strain failed to 
produce granulomatous inflammation.35 Thus, targeting GroEL1 with small molecule 
inhibitors might be effective at preventing the formation of granulomas that contribute to 
latent disease, or targeting bacteria that are already present in established granulomas. These 
enticing findings suggest that a small molecule that could concurrently inhibit both GroEL1 
and GroEL2 in M. tuberculosis might be effective at treating active and latent stages of 
tuberculosis, which would be superior to current tuberculosis therapeutics.
Towards our goal of exploiting HSP60/10 and GroEL/ES chaperonin systems as an 
antibiotic strategy, we previously reported a high-throughput screen for small molecule 
inhibitors of the E. coli GroEL/ES chaperonin system.41 This initial study identified 
compound 1 as one of our most potent GroEL/ES inhibitors (Figure 1A). Our subsequent 
study found 1 lacked any appreciable antibacterial efficacy against a panel of Gram-positive 
and Gram-negative bacteria known as the ESKAPE pathogens – an acronym that stands for 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species.42 However, our third study 
identified isostructural benzoxazole analogs (2–14, Figure 1B) that exhibit antibiotic effects 
against Trypanosoma brucei parasites, the causative agents of African sleeping sickness. 
43We refer to these as “pseudosymmetric full-molecules” as they have two sulfonamide end-
capping groups with R1 substructures being identical on both the right and left-hand sides of 
the molecule. Furthermore, our fourth study identified 2-chlorothiophene-based analogs (15, 
16R-34R, and 16L-34L, Figure 1C) that exhibited antibiotic effects against Gram-positive 
bacteria, in particular Staphylococcus aureus and methicillin-resistant S. aureus (MRSA).44 
We refer to these as “asymmetric full-molecules” as they have two sulfonamide end-capping 
groups, but the substructures differ between the Right- and Left-hand sides of the molecule 
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(i.e. R- and L-series full-molecules). Since the M. tuberculosis GroEL1 and GroEL2 
homologs share 52% and 59% sequence identity with E. coli GroEL, respectively, we 
reasoned that they may also exhibit antibiotic effects against M. tuberculosis. Thus, in the 
present study, we evaluated the previously developed compound 1 analogs for their ability to 
inhibit M. tuberculosis growth in liquid media (see discussion below). Because we were 
unsure whether or not these compounds required both of the sulfonamide end-capping 
groups to maintain potent inhibition, we developed a new series that we term “half-
molecules”, as they contain only one sulfonamide end-capping group on either the Right- or 
Left-hand sides of the molecule (R- and L-series half-molecules, Figure 1D). We also 
wanted to determine whether simplifying inhibitors in this manner might reduce the 
cytotoxicity of this series to human cells, while still maintaining antibiotic efficacy.
Another possible strategy to treat tuberculosis infections is by targeting a virulence factor 
that M. tuberculosis secretes into the cytoplasm of host macrophages, protein tyrosine 
phosphatase B (PtpB). By secreting PtpB into the cytosol of host macrophages, M. 
tuberculosis disrupts host cell immune responses by blocking ERK1/2 and p38 mediated 
IL-6 production and promoting host cell survival by interfering with Akt signaling.45 
Deletion of PtpB has been shown to block intracellular survival of M. tuberculosis in IFN-γ 
activated macrophages and reduce the bacterial load in a guinea pig model.45, 46 Several 
studies have shown the possibility of selectively inhibiting M. tuberculosis PtpB over human 
phosphatases, which can result from structural differences such as PtpB containing alpha-
helices that can occlude the active site, yet are mobile enough to allow substrate and 
competitive inhibitors to bind.45, 47–54 Furthermore, previous studies have demonstrated the 
feasibility of inhibiting M. tuberculosis PtpB with small molecules and reducing bacterial 
loads in macrophages.45, 47, 48
In their 2007 study, Grundner et al. reported a crystal structure of PtpB in complex with the 
selective inhibitor (oxalylamino-methylene)-thiophene sulfonamide (OMTS – Figure 2A).50 
In that structure, two OMTS molecules were found bound in the crystal structure, with the 
sulfonamides of each interacting with a number of ordered water molecules and binding site 
residues (e.g. Arg59, Arg63, His94, Glu129, and Arg136). Examining the crystal structure, 
we were intrigued that the sulfonamides of each OMTS molecule reside ~11–12 Åapart 
from one another (Figure 2B). Since the two sulfonamides of our compound 1 analogs are 
also ~11–12 Å apart (albeit in a head-to-head configuration, whereas the OMTS 
sulfonamides are head-to-tail), we envisioned that our analog series might also be capable of 
inhibiting M. tuberculosis PtpB in a conformation that would bridge across the two OMTS 
binding sites, making similar polar interactions as OMTS, while positioning the sulfonamide 
end-capping groups upwards to what would be the phosphotyrosine active site catalytic 
residues and adjacent pocket. This raises the enticing possibility that this class of molecules 
could inhibit the two M. tuberculosis GroEL homologs to target actively replicating 
mycobacteria and dormant mycobacteria in granulomas, as well as inhibit PtpB to target 
intracellular M. tuberculosis that are evading host cell immune responses. Thus, this class of 
inhibitors could be effective against all stages of M. tuberculosis infection. The present study 
was designed to explore such dual-targeting GroEL/ES and PtpB inhibitors in vitro and in 
cell culture, with future studies envisioned to build from the established structure-activity 
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relationships (SAR) to further optimize lead candidates for evaluating in animal infection 
models.
Extending from our previous studies that explored the bis-sulfonamide full-molecule series 
(compounds 1–34 – see Tables S1–S4 in the Supporting Information), we synthesized a 
library of half-molecule analogs that had the R3-substituted sulfonamide end caps on either 
the Right (R-series) or Left (L-series) sides of the 2-phenylbenzoxazole core (Scheme 1).
43, 44 Representative synthetic protocols for the sulfonamide coupling and methoxy-to-
hydroxy deprotection reactions are presented in the Supporting Information along with 
complete compound characterizations (1H-NMR, MS, and RPHPLC). These syntheses 
resulted in the development of 58 new half-molecules – 29 each of the R- and L-series 
analogs. As we previously found that aryl-sulfonamides were the most potent GroEL/ES 
inhibitors, we developed analogs bearing substituted phenyl-sulfonamides. Furthermore, we 
biased the analogs to contain a variety of halide substituents and substitution patterns as our 
previous antibacterial study indicated that halide-bearing compounds were typically more 
effective at inhibiting bacterial proliferation than compounds with other substituents.44
We next employed a series of established biochemical assays to evaluate the inhibitory 
effects of the new half-molecules against the GroEL/ES chaperonin system.41–44, 55 For 
these assays, we used E. coli GroEL/ES as a surrogate, as obtaining functional GroEL 
oligomeric rings from M. tuberculosis has so far proven difficult.12, 36, 37, 39 However, we 
anticipate a high probability that inhibitors would bind to and inhibit the GroEL/ES 
chaperonin systems in M. tuberculosis since E. coli GroEL shares 52% identity with the 
GroEL1 homolog, and 59% identity with GroEL2. We employed two chaperonin-mediated 
folding assays using malate dehydrogenase (MDH) and rhodanese (Rho) as the unfolded 
reporter enzymes. We have described these assays elsewhere, and have included detailed 
protocols of each in the Supporting Information.41–44, 55 Briefly, these are coupled assays 
where we monitor the enzymatic activity of two reporter enzymes (MDH and Rho), which 
are denatured and then get efficiently refolded by GroEL/ES in the absence of inhibition. We 
further counter-screened compounds for their ability to inhibit native MDH and Rho to 
identify false-positives that inhibit the enzymatic reporter reactions of the refolding assays. 
IC50 results for the testing of compounds in these assays are shown in Tables S5A–S6A in 
the Supporting Information. The pseudosymmetric and asymmetric full-molecules had been 
evaluated in these assays in our previous studies, and thus we refer readers to those 
publications for a detailed account of their results.43, 44
As visualized in the correlation plot in Figure 3A, compounds were nearly equipotent at 
inhibiting in both of the GroEL/ES-mediated folding assays (Spearman correlation 
coefficient is 0.923,p < 0.0001). As SAR for the full-molecule series has been more 
thoroughly discussed for these assays in our previous studies,43, 44 we will primarily present 
comparisons between the full vs. half-molecule scaffolds herein. In this context, the full-
molecules were dramatically more potent than the half-molecules, indicating that the 
presence of both aryl-sulfonamide substructures are required for potent inhibition. While 
some compounds were found to inhibit in either the native MDH or Rho reporter activity 
counter-screens, only one previously reported compound (28R) inhibited in both native 
assays, and only weakly (Figure 3B).43, 44 As the IC50 values for all the compounds in the 
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native MDH and Rho reporter counter-screens were much higher than in the corresponding 
refolding assays, these results support that compounds were on target for inhibiting the 
GroEL/ES-mediated folding cycle.
We next evaluated how effective our GroEL/ES inhibitors would be at inhibiting the growth 
of M. tuberculosis in liquid culture, as inhibiting the essential GroEL2 homolog should be 
bactericidal. We tested the ability of each compound to inhibit growth at a fixed 
concentration of 200 μM after 5 days (see the Supporting Information for the assay 
protocol).56 Compounds exhibiting >50% inhibition were then tested as serial dilutions in 
order to determine EC50 values, defined as the concentration at which growth was inhibited 
by 50%. Percent inhibition and EC50 results are presented in Tables S1–S6 in the Supporting 
Information. Intriguingly, while the half-molecules were twice as likely to exhibit >50% 
inhibition at the single 200 μM test concentration (28/58, or 48%) compared to the full-
molecules (22/89, or 25%), the only analogs with EC50s <100 μM were the full molecules. 
This latter finding was not entirely surprising since the full-molecules were much more 
potent GroEL/ES inhibitors than the half-molecules. While this coarse SAR helps support 
that inhibitors are on target for GroEL/ES in mycobacteria, we note only a weak correlation 
between M. tuberculosis EC50 results compared to IC50 results for the GroEL/ES-dMDH 
refolding assay (Figure 3C – Spearman correlation coefficient is 0.439, p = 0.0011). More 
thorough experiments need to be conducted in the future to conclusively determine the 
mechanism of action in cells. While the most potent compounds exhibited only moderate 
EC50s in the 20–30 μM range, these were encouraging results since this was the first 
exploratory study we have conducted to see whether or not GroEL/ES inhibitors would have 
antibiotic efficacy against M. tuberculosis. Thus, the current results have provided valuable 
insights to guide future pharmacological optimization studies.
A potential caveat to targeting GroEL/ES chaperonin systems as an antibiotic strategy is that 
human cells contain homologous machinery in their mitochondria. Human mitochondrial 
HSP60 shares 48% sequence identity with E. coli GroEL (similar to the M. tuberculosis 
GroEL1 and GroEL2 homologs), which raises the possibility of potential HSP60-dependent 
cytotoxicity to human cells. However, as we continue to study this and other chaperonin 
inhibitor scaffolds, we become less and less concerned with potential cytotoxicities 
associated with targeting human HSP60/10. In many instances, compounds that we have 
found to inhibit HSP60/10 in vitro exhibit low-to-no cytotoxicity when tested in our liver 
and kidney cell viability assays.42, 43, 55 Furthermore, we have recently identified numerous 
known drugs and natural products that are able to inhibit HSP60/10 in vitro.43, 55, 57 For 
example, while we found that suramin can inhibit human HSP60/10 in vitro, it has been 
safely used for over 100 years as a first-line therapeutic for treating African sleeping 
sickness, which is caused by Trypanosoma brucei parasites. Nonetheless, we continue to 
counter-screen compounds in our standard HSP60/10-dMDH refolding assay as it does 
prove useful for helping to understand inhibitor mechanisms of action at the protein level. 
This assay is analogous to the GroEL/ES-dMDH assay so that IC50 results can be directly 
compared between the two chaperonin systems. A detailed protocol is presented in the 
Supporting Information, with results for the half-molecules presented in Tables S5A–S6A. 
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For an account of results for the pseudosymmetric and asymmetric full-molecules, we refer 
readers to our previous studies.43, 44
As we observed with GroEL/ES, the full-molecules were more potent at inhibiting 
HSP60/10 than the half-molecules (Figure 4A). While some compounds were nearly 
equipotent between the two chaperonin systems, many exhibited selectivity towards E. coli 
GroEL/ES. We previously noted this SAR for the pseudosymmetric (1–15) and R-series 
asymmetric full molecules (16R-34R), demonstrating that it is possible to tune this scaffold 
to selectively target GroEL/ES.43, 44 However, as noted above, this may be inconsequential 
for cytotoxicity purposes as the mitochondrial membrane is highly impermeable to 
penetration by small molecules, and thus inhibitors may never reach HSP60/10 in the 
mitochondrial matrix.
As a moderate-throughput first-pass indicator of cellular toxicity, we typically employ two 
Alamar Blue-based cell viability assays, where compounds are incubated with human liver 
(THLE-3) and kidney (HEK 293) cells over a 48 h time period. A detailed protocol for these 
assays is presented in the Supporting Information, with cell viability results (cytotoxicity 
CC50 values) presented in Tables S5B–S6B. We again refer readers to our previous studies 
for cell viability CC50 results for the pseudosymmetric and asymmetric full-molecules 
(compounds 1–34).43, 44 Similar to results from the biochemical assays, the full-molecules 
were more potent inhibitors (i.e. more cytotoxic) than the half-molecules were in the two 
cell viability assays (Figure 4B). However, we note that there is a poor correlation when 
comparing IC50 and CC50 results from the HSP60/10-dMDH and cell viability assays 
(Figure 4C – Spearman correlation coefficient is 0.244, p = 0.0027 when comparing with 
liver cells), which could indicate off-target effects not related to inhibiting the HSP60/10 
chaperonin system, and/or potential cell or mitochondrial permeability differences between 
compounds. These possibilities highlight that results from the cell viability assays are the 
critical indicators of potential cytotoxic effects that may be encountered in vivo.
While the above results support the feasibility of identifying GroEL/ES inhibitors that can 
kill actively replicating M. tuberculosis, we were particularly intrigued by the possibility of 
this series also being able to target the protein tyrosine phosphatase B (PtpB) virulence 
factor that intracellular M. tuberculosis secrete into macrophages to evade host cell immune 
responses. To investigate this possibility, we obtained a His-tagged version of M. 
tuberculosis PtpB, which was previously developed by Grundner et al., to generate 
recombinantly-expressed and purified enzyme.49, 50 Following previously reported 
procedures by Zhou et al., which monitored for phosphatase activity using paranitrophenyl 
phosphate (pNPP), we evaluated all compounds in dose-response format to obtain IC50 
values.45, 47, 49, 50 As a preliminary indication of selectively targeting M. tuberculosis PtpB, 
we counter-screened against three human phosphatases, PTPN1 (PTP1B), PTPN2 (TCPTP), 
and PTPN5 (STEP), using analogous procedures. Detailed protocols are presented in the 
Supporting Information for these assays, with IC50 results for all compounds presented in 
Tables S1–S6.
While both the full- and half-molecules were able to inhibit M. tuberculosis PtpB 
phosphatase activity, as noted above for the other assays, the full-molecules were generally 
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more potent than the half-molecules (Figure 5A). An interesting discovery was that, while 
the full-molecules all inhibit M. tuberculosis PtpB activity with increasing compound 
concentrations, most half-molecules exhibit a biphasic response first activating, then 
inhibiting phosphatase activity (Figure 5B). This could be the result of two half-molecules 
binding to PtpB in a manner like that previously observed for OMTS.50 Thus, binding of the 
first molecule at the distal part of the active site may open the alpha-helical lid, allowing 
pNPP to more effectively occupy the proximal part next to the catalytic residues. Then at 
higher concentrations, the second half-molecule could competitively displace the pNPP, 
thereby showing inhibition. It should be noted, though, that this may be an artifact of this 
particular assay protocol using pNPP, as binding to either site would theoretically compete 
with a phosphorylated peptide. Thus, IC50 values could be more potent in a physiological 
context than what we have reported (presuming binding affinities were high enough), 
although future studies would need to confirm this.
While we were excited to see so many GroEL/ES inhibitors were also able to potently 
inhibit PtpB, we were intrigued that such a high correlation was observed between the two 
data sets (Spearman correlation coefficient is 0.756, p < 0.0001) as there is no a priori reason 
why the binding sites of GroEL and PtpB would be similar. However, we note that the SAR 
is relatively flat for the full-molecules for inhibiting PtpB (i.e. most are within the 1–10 μM 
range), which could be consistent with the bissulfonamide core predominantly contributing 
to binding affinity and the end-capping groups not fully occupying the remainder of the 
active site. This is important since, on the whole, this scaffold class exhibits only slight 
selectivity for M. tuberculosis PtpB over the three human phosphatases (Figure 6). Thus, 
with extra space that compounds could more fully occupy in the active site, there should be 
room to optimize inhibitor potency and selectivity profiles against M. tuberculosis PtpB. 
This also boosts confidence that there should be ample chemical space to simultaneously 
optimize inhibition of GroEL/ES and PtpB function to target M. tuberculosis in both active 
and latent stages of infection. Such optimization studies will be the focus of future 
investigations.
In summary, in the present study, we evaluated whether or not a series of GroEL/ES 
inhibitors, based on the compound 1 scaffold, would be effective at inhibiting the growth of 
M. tuberculosis. Furthermore, we envisioned that these could be dual-targeting molecules 
capable of inhibiting the M. tuberculosis GroEL/ES chaperonin systems as well as the PtpB 
virulence factor that they secrete into macrophages. This study identified 14 GroEL/ES 
inhibitors that exhibited EC50 values <100 μM against M. tuberculosis growth in liquid 
culture (Table 1). We have categorized these into three groups, depending on their selectivity 
profiles for inhibiting GroEL/ES over human HSP60/10, as well as for inhibiting M. 
tuberculosis PtpB over the panel of three human phosphatases. Compounds within the blue 
category exhibit selectivity for both GroEL/ES and PtpB; compounds within the green 
category exhibit selectivity for either GroEL/ES or PtpB, but not both; and compounds in the 
yellow category are not inherently selective. From our continued studies, though, we note 
that even if compounds can inhibit human HSP60/10 in vitro, many exhibit only low or no 
cytotoxicity to human cells. Furthermore, as PtpB is highly adaptable to compounds that 
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bind within the active site, there should still be ample chemical space to optimize inhibitors 
for binding affinity, efficacy, and selectivity.
Two of the lead compounds we identified were 20R and 20L, which had primary amines 
either on the right or left-hand sides of the scaffold. These were unique compounds within 
this study as they were the only analogs to contain primary amines that would be charged 
under physiological conditions. Thus, future studies will explore new analogs that contain 
amines on either the right or left-hand sulfonamides, while varying groups on the other side. 
The 2h-o/m/p analogs were also unique lead molecules – the only hydroxylated full-
molecule analogs – to which a similar SAR strategy will be applied. In either case, 
additional areas of exploration to optimize inhibitors are varying the sulfonamide linkers and 
employing scaffolds other than the 2-phenylbenzoxazole core. By doing so, we are 
optimistic that we will be able to enhance the potency and selectivity of lead inhibitors for 
M. tuberculosis GroEL/ES chaperonin systems and PtpB, and increase their selectivity 
indices for inhibiting M. tuberculosis proliferation over cytotoxicity to human cells. Once 
we have developed more viable lead candidates, we will pursue additional studies looking at 
the effects of inhibiting M. tuberculosis PtpB in macrophage models, as well as antibiotic 
efficacy in an in vivo infection model. With an antibiotic strategy that concomitantly inhibits 
the two M. tuberculosis GroEL homologs and PtpB, these polypharmacologic agents are 
predicted to target actively replicating bacteria, intracellular bacteria that are evading host 
cell immune responses, and dormant bacteria that have formed granulomas. Thus, we are 
hopeful that this could be an effective strategy for treating all stages of tuberculosis.
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Progression of compound 1 analog development and evaluation through our recent studies.
41–44 In each panel, the R1-R3 groups represent a variety of alkyl, aryl, and ortho-, meta-, 
and para-substituted phenyl substructures (refer to the Tables S1–S6 in the Supporting 
Information for specific R-substructures). Each successive study (panels A-C) included 
testing of compounds developed from the previous studies in order to more thoroughly 
characterize SAR. Panel D presents compounds newly developed in the current study, which 
we term “half-molecules” as they contain only one sulfonamide end-capping group on either 
the Right- or Left-hand sides of the molecules (R- and L-series half-molecules). We have 
evaluated these, as well as all the previously-developed “full-molecules” (i.e. two 
sulfonamide end-capping groups as shown in panels A-C), for their ability to inhibit the 
proliferation of M. tuberculosis, as well as the protein tyrosine phosphatase B (PtpB) 
virulence factor that they secrete into macrophages to evade host cell immune responses.
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A. Grundner et al. previously reported that the OMTS compound was a potent and selective 
inhibitor of M. tuberculosis PtpB.50 B. Two OMTS molecules were found occupying the 
active site of M. tuberculosis PtpB (PDB ID 2OZ5). On examination, the sulfonamides of 
each OMTS molecule reside ~11–12 Å apart, similar to our compound 1 analogs. Thus, we 
envisioned compound 1 analogs might be able to bind in a manner that bridges the distal and 
proximal parts of the active site. In such a conformation, the sulfonamides could interact 
with the binding site similarly to those of OMTS, with the R-substructures pointing upwards 
to fill the binding cavity and engaging the catalytic residues located in the proximal part of 
the active site.
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Correlation plots of IC50 and EC50 values for compounds tested in the respective GroEL/ES-
dMDH and dRho refolding assays (A), native MDH and Rho reporter counter-screens (B), 
and M. tuberculosis proliferation assay (C). Each data point represents results for an 
individual compound (plotted from results presented in Tables S1–S6 in the Supporting 
Information). Full molecules (i.e. compounds 1–34) are represented by blue circles, and 
half-molecules (i.e. compounds 35–51) are represented by yellow squares. A & B. 
Compounds inhibit nearly equipotently in the GroEL/ES-dMDH and -dRho refolding assays 
(Spearman correlation coefficient is 0.923, p < 0.0001), but are weak or inactive in the native 
MDH or Rho enzymatic reporter counter-screens, supporting on-target effects for inhibiting 
chaperonin-mediated substrate refolding. As indicated in panel A, we consider compounds 
with IC50 values plotted in the grey zones to be inactive (i.e. greater than the maximum 
concentrations tested), >30 μM to be weak inhibitors, 10–30 μM moderate inhibitors, 1–10 
μM potent inhibitors, and <1 μM very potent and acting near stoichiometrically since the 
concentration of GroEL subunits is 700 nM. C. Some GroEL/ES inhibitors exhibit weak-to-
moderate inhibition of M. tuberculosis proliferation, but the correlation with inhibiting 
GroEL/ES refolding functions in vitro is weak (Spearman correlation coefficient is 0.439, p 
= 0.0011). Compounds showing <50% inhibition of M. tuberculosis proliferation when 
tested at a single 200 μM concentration were excluded from this analysis.
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Correlation plots of IC50 and CC50 values for compounds tested in the respective GroEL/ES-
dMDH and HSP60/10-dMDH refolding assays (A), and liver/kidney cell viability assays (B 
& C). A. While many compounds inhibit human HSP60/10 nearly as well as E. coli 
GroEL/ES (Spearman correlation coefficient for all molecules is 0.740, p < 0.0001), we 
previously reported being able to tune for selectivity with the pseudosymmetric and 
asymmetric R-series full molecules.43, 44 B. Cytotoxicities of compounds are comparable 
between human THLE-3 liver and HEK 293 kidney cells (Spearman correlation coefficient 
is 0.857, p < 0.0001). C. HSP60/10 inhibitors exhibit weak-to-moderate cytotoxicity to 
human THLE-3 liver cells, with a low correlation evident between the two assays (Spearman 
correlation coefficient is 0.244, p = 0.0027).
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A. Correlation plot of IC50 values for compounds tested in the GroEL/ES-dMDH refolding 
and M. tuberculosis PtpB phosphatase assays (Spearman correlation coefficient is 0.756, p < 
0.0001). B. Dose-response curves for analogs 2h-m, R51-m, and L51-m evaluated in the M. 
tuberculosis PtpB phosphatase assay. While the full-molecules all inhibit M. tuberculosis 
PtpB phosphatase activity with increasing compounds concentrations, most half-molecules 
exhibit a bi-phasic response where compounds activate then inhibit phosphatase activity, to 
varying extents, as shown for analogs R51-m and L51-m. Data point errors represent 
standard deviations from 6–8 replicates.
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Correlation plots of IC50 values for compounds tested against the M. tuberculosis PtpB 
phosphatase compared to the human PTPN1 (PTP1B, panel A), PTPN2 (TCPTP, panel B), 
and PTPN5 (STEP, panel C). While some individual compounds are able to selectively 
inhibit the M. tuberculosis PtpB over the human phosphatases, on the whole, this scaffold 
class only exhibits a slight selectivity for the bacterial phosphatase – Spearman correlation 
coefficients are 0.828 (p < 0.0001) for PTPN1, 0.755 (p < 0.0001) for PTPN2, and 0.786 (p 
< 0.0001) for PTPN5.
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Table 1.
Biochemical and cell-based assay results for lead analogs exhibiting M. tuberculosis proliferation EC50 values 
<100 μM. Fold-selectivities for inhibiting GroEL/ES over human HSP60/10, and M. tuberculosis PtpB over 
the three human phosphatases, are shown in brackets in the shaded columns. Compounds colored blue exhibit 
>5x selectivities for both GroEL and PtpB; compounds colored green exhibit >5x selectivities for either 
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GroEL or PtpB (but not both); and compounds colored yellow exhibit between 1–5x selectivities for GroEL or 
PtpB.
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